S100A9 and early-onset autosomal dominant Alzheimer disease: Due to its inherent amyloidogenicity, S100A9 may play a more important role in PD pathology than merely being one of the disease-related pro-inflammatory mediators: it may contribute to the development of the PD amyloid-neuroinflammatory cascade in a similar way as shown previously in Alzheimer’s disease [18].